[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","yp4pj76onclkwmfghif58ee6w","revision",2,"title","Cellyan Biotechnology 1-for-20 反向股票拆分公告","originalTitle","6-K - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)","summary","Cellyan Biotechnology 宣布实施 1 对 20 反向股票拆分。该公告作为 6-K 文件提交至美国证券交易委员会。公司为开曼群岛注册的生物技术公司。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":57,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-10-21T12:00:01.000Z","discoveredAt","2026-10-21T12:07:15.610Z","timelineAt","category","tip","tags",[81,82,83],"stockSymbols",[80],"score",21,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":14,"_68":69,"_70":71},"hasTranslation","bodyLanguage","original","factId","f3gVUWUFHUXY",{"_72":73,"_15":74},"reportCount","additionalSourceCount",1,"developmentCount",0,"publicId","37315703-57f2-4536-9111-b843514f3e5f","Cellyan Biotechnology 反向股票拆分",{"_72":73,"_15":74},"zh","

UNITED\nSTATES

SECURITIES\nAND EXCHANGE COMMISSION

WASHINGTON,\nD.C. 20549

FORM\n6-K

REPORT\nOF FOREIGN PRIVATE ISSUER
\nPURSUANT TO RULE 13a-16 OR 15d-16 OF THE
\nSECURITIES EXCHANGE ACT OF 1934

For\nthe month of October 2026

Commission\nFile Number 001-42468

CELLYAN\nBIOTECHNOLOGY CO., LTD
\n(Translation of registrant’s name into English)

Room\nB1, 5/F., Well Town Industrial Building,
\n13 Ko Fai Road, Yau Tong, Kowloon
\nHong Kong
\n(Address of principal executive offices)

Indicate\nby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form\n20-F ☒ Form 40-F ☐

Cellyan\nBiotechnology Co., Ltd, a Cayman Islands company (the “Company”), furnishes under the cover of Form 6-K the following.

The\ninformation contained in this Report on Form 6-K, including Exhibit 99.1 hereto, is hereby incorporated by reference into the Company’s\nregistration statement on Form\nF-3 (File No. 333-296754) and S-8\n(Registration No. 333-298301).

EXHIBIT\nINDEX

\n \n \n \n \n \n \n \n \n

Exhibit\n No.		Description
99.1		Press release - Cellyan Biotechnology Announces a 1-for-20 Reverse Stock Split

SIGNATURES

Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned, thereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Date:\n October 21, 2026	CELLYAN\n BIOTECHNOLOGY CO., LTD

	By:	/s/\n Chenyu Liang
		Chenyu\n Liang
		Director\n and Chief Executive Officer

","zhKind","complete","HKPD","政策与监管","退市","停复牌","aihot","/items/yp4pj76onclkwmfghif58ee6w","https://www.sec.gov/Archives/edgar/data/2007702/000121390026111190/0001213900-26-111190-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792800000&sig=a1281a539589308a","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792800000&sig=57a86ea6a382db0f 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792800000&sig=f9807010575fb678 96w","changelogVersion","2026-10-01T08:00"]